A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor

Author： Alousi Amin Boinpally Ramesh Wiegand Richard Parchment Ralph Gadgeel Shirish Heilbrun Lance Wozniak Antionette DeLuca Pamela LoRusso Patricia

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.25, Iss.2, 2007-04, pp. : 147-154

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

HIV-1 Associated Topoisomerase II&bgr; Kinase: A Potential Pharmacological Target for Viral Replication

Current Pharmaceutical Design, Vol. 19, Iss. 26, 2013-08 ,pp. : 4776-4786

Bentham Science Publishers

Access to resources Recommend Favorite

The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models

By Ochi T. Motoyama Y. Goto T.

European Journal of Pharmacology, Vol. 391, Iss. 1, 2000-03 ,pp. : 49-54

Elsevier

Access to resources Recommend Favorite

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

By Kang Yoon-Koo Muro Kei Ryu Min-Hee Yasui Hirofumi Nishina Tomohiro Ryoo Baek-Yeol Kamiya Yukimasa Akinaga Shiro Boku Narikazu

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 355-361

Springer Publishing Company

Access to resources Recommend Favorite

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 10, 2012-10 ,pp. : 1233-1249

Informa Healthcare

Access to resources Recommend Favorite

Camptothecin and Podophyllotoxin Derivatives: Inhibitors of Topoisomerase I and II – Mechanisms of Action, Pharmacokinetics and Toxicity Profile

By Hartmann Jörg T.

Drug Safety, Vol. 29, Iss. 3, 2006-01 ,pp. : 209-230

Adis International

Access to resources Recommend Favorite